Maruyama Y, van Nagell J R, Yoneda J, Donaldson E, Gallion H, Higgins R, Powell D, Turner C, Kryscio R
Department of Radiation Medicine, University of Kentucky Medical Center, Lexington 40536.
J Natl Cancer Inst. 1988 Jun 1;80(7):501-6. doi: 10.1093/jnci/80.7.501.
A fast-neutron-emitting radioisotope, 252Cf, is being tested in clinical trials of neutron brachytherapy for cervical cancer. The efficacy for histological eradication of bulky stage IB cervical tumors (mean diameter, approximately 6 cm) using combined radiation and surgery was studied in 65 patients treated with 137Cs or 252Cf before surgery during 1983-1986. Forty-four patients were treated with 137Cs and 21 were treated with 252Cf at equivalent doses of radiation. Fifteen of the 44 specimens (34%) were positive after 137Cs therapy. Only one of the 21 specimens was positive after 252Cf therapy (P = .025), and that patient was treated in a delayed schedule 21 days after the start of external-beam irradiation rather than early in the course. 252Cf therapy required a much lower radiation dose and shorter treatment time. The study compared tumor destruction of an identically staged human cervical tumor in situ by direct histological means, using 252Cf neutron therapy or conventional photon therapy at an identical and equivalent dose adjusted by a relative biological effectiveness of 6.0 for 252Cf.
一种发射快中子的放射性同位素锎 - 252（²⁵²Cf）正在用于宫颈癌中子近距离治疗的临床试验。1983年至1986年期间，对65例在手术前接受¹³⁷Cs或²⁵²Cf治疗的患者进行了研究，以探讨联合放疗和手术对大体IB期宫颈癌肿瘤（平均直径约6厘米）组织学根除的疗效。44例患者接受¹³⁷Cs治疗，21例患者接受等效剂量的²⁵²Cf治疗。¹³⁷Cs治疗后，44个标本中有15个（34%）呈阳性。²⁵²Cf治疗后，21个标本中只有1个呈阳性（P = 0.025），且该患者是在外照射开始21天后延迟进行治疗，而非在疗程早期。²⁵²Cf治疗所需的辐射剂量低得多，治疗时间也更短。该研究通过直接组织学方法，比较了在相同分期的人原位宫颈癌肿瘤中，使用²⁵²Cf中子治疗或常规光子治疗在相同且等效剂量下（根据²⁵²Cf的相对生物效应调整为6.0）对肿瘤的破坏情况。
